Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2023）
摘要
Our data suggest that BIC/FTC/TAF + darunavir/cobicistat is an effective, well-tolerated regimen that may improve convenience and, potentially, long-term success in stable heavily pre-treated PLWH.
更多查看译文
关键词
darunavir/cobicistat,bictegravir/emtricitabine/tenofovir alafenamide,antiretroviral-experienced,hiv-infected
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要